Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,141 to 1,160 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis. | BMC Bioinformatics | 2022 | 35941550 | PubTator, text mining | PubMed |
| Common Core Genes Play Vital Roles in Gastric Cancer With Different Stages. | Front Genet | 2022 | 35938042 | PubTator, text mining | PubMed |
| Research Progress for RNA Modifications in Physiological and Pathological Angiogenesis. | Front Genet | 2022 | 35937999 | PubTator, text mining | PubMed |
| The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer. | Front Oncol | 2022 | 35936737 | PubTator, text mining | PubMed |
| Bioinformatics Analysis Revealing the Correlation between NF-κB Signaling Pathway and Immune Infiltration in Gastric Cancer. | Comput Math Methods Med | 2022 | 35936362 | PubTator, text mining | PubMed |
| IGF2BP1, a New Target to Overcome Drug Resistance in Melanoma? | Front Pharmacol | 2022 | 35935853 | PubTator, text mining | PubMed |
| Identifying potential prognosis markers in hepatocellular carcinoma via integrated bioinformatics analysis and biological experiments. | Front Genet | 2022 | 35928445 | PubTator, text mining | PubMed |
| Long noncoding RNA CERS6-AS1 modulates glucose metabolism and tumor progression in hepatocellular carcinoma by promoting the MDM2/p53 signaling pathway. | Cell Death Discov | 2022 | 35927226 | PubTator, text mining | PubMed |
| Relieving DYRK1A repression of MKL1 confers an adult-like phenotype to human infantile megakaryocytes. | J Clin Invest | 2022 | 35925681 | PubTator, text mining | PubMed |
| Inhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia. | Leukemia | 2022 | 35915142 | PubTator, text mining | PubMed |
| Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma. | Front Immunol | 2022 | 35911718 | PubTator, text mining | PubMed |
| Identification of Nine M6A-Related Long Noncoding RNAs as Prognostic Signatures Associated with Oxidative Stress in Oral Cancer Based on Data from The Cancer Genome Atlas. | Oxid Med Cell Longev | 2022 | 35910847 | PubTator, text mining | PubMed |
| RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma. | Front Pharmacol | 2022 | 35910358 | PubTator, text mining | PubMed |
| CircPDSS1 promotes the proliferation, invasion, migration, and EMT of breast cancer cell via regulating miR-320c/CKAP5 axis. | Cancer Cell Int | 2022 | 35902921 | PubTator, text mining | PubMed |
| Molecular and Circulating Biomarkers of Gastric Cancer. | Int J Mol Sci | 2022 | 35886934 | PubTator, text mining | PubMed |
| circRNA: A New Biomarker and Therapeutic Target for Esophageal Cancer. | Biomedicines | 2022 | 35884948 | PubTator, text mining | PubMed |
| Role of Circular RNA in Brain Tumor Development. | Cells | 2022 | 35883576 | PubTator, text mining | PubMed |
| Circular RNA circ-TNPO3 inhibits clear cell renal cell carcinoma metastasis by binding to IGF2BP2 and destabilizing SERPINH1 mRNA. | Clin Transl Med | 2022 | 35876041 | PubTator, text mining | PubMed |
| Comprehensive Analysis of Immune Cell Infiltration of m6a-Related lncRNA in Lung Squamous Cell Carcinoma and Construction of Relevant Prognostic Models. | Biomed Res Int | 2022 | 35872842 | PubTator, text mining | PubMed |
| PLAA suppresses ovarian cancer metastasis via METTL3-mediated m6A modification of TRPC3 mRNA. | Oncogene | 2022 | 35869392 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=58